Molecular Targets in Alveolar Rhabdomyosarcoma: A Narrative Review of Progress and Pitfalls

Area of Science:

• Oncology
• Molecular Biology
• Pediatric Cancer Research

Background:

• Alveolar rhabdomyosarcoma (ARMS) is an aggressive pediatric soft-tissue sarcoma.
• Fusion proteins, specifically PAX3/7-FOXO1, are the primary drivers of ARMS.
• Current therapies offer limited success for fusion-positive ARMS patients.

Purpose of the Study:

• To review recent advances in the molecular pathogenesis of ARMS.
• To identify key diagnostic and therapeutic targets for ARMS.
• To provide a framework for developing improved, targeted therapies.

Main Methods:

• Literature review of recent advances in ARMS molecular pathogenesis.
• Analysis of key molecular drivers, biomarkers, and therapeutic targets.
• Evaluation of emerging therapeutic strategies including immunotherapy and epigenetic modifiers.

Main Results:

• PAX3/7-FOXO1 fusion proteins drive ARMS by reprogramming transcription, impairing differentiation, and activating super-enhancers.
• Emerging biomarkers include YAP, TFAP2B, and P-cadherin.
• Potential therapeutic targets encompass oncogenic kinases (Aurora A, CDK4, PLK1), receptor tyrosine kinases (FGFR, MET), and transcription factors (FOXF1, ETS1).

Conclusions:

• Understanding ARMS molecular drivers is crucial for therapeutic development.
• Biomarker-guided, multi-targeted therapies offer promise for improving ARMS patient outcomes.
• Further research into immunotherapies, epigenetic modifiers, and noncoding RNAs may yield novel treatment strategies.